Health Care & Life Sciences » Biotechnology | Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Inc.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
85.32 M
Public Float
-
Aurinia Pharmaceuticals Inc.
Stock Exchange NASDAQ Stock Market
EPS
$0.71
Market Cap
$591.12 M
Shares Outstanding
84.48 M
Public Float
-
Aurinia Pharmaceuticals Inc.
Stock Exchange Toronto Stock Exchange Prices
EPS
CAD0.94
Market Cap
CAD770.74 M
Shares Outstanding
78.45 M
Public Float
52.94 M

Profile

Address
4464 Markham Street
Victoria British Columbia V8Z 7X8
Canada
Employees -
Website http://www.auriniapharma.com
Updated 07/08/2019
Aurinia Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases particularly lupus nephritis. The company was founded by Robert Foster, Richard Glickman and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada. .

Financials

View All
Created with Highcharts 5.0.14Aurinia Pharmaceuticals Inc.Net Income. Fiscal year is January-December. All values CAD Thousands.2 7422 74218 38518 38523 80523 80530 86430 86491 88891 88883 10983 109201320142015201620172018025k50k75k100k
Created with Highcharts 5.0.14Aurinia Pharmaceuticals Inc.Sales/Revenue. Fiscal year is January-December. All values CAD Thousands.998998307307300300229229545545600600201320142015201620172018025050075010001250

Richard M. Glickman
Chairman & Chief Executive Officer
Michael R. Hayden
Director